Mark Sheptoff Financial Planning buys $2,032,881 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Mark Sheptoff Financial Planning scooped up 517 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 45,125 shares of Abbott Laboratories which is valued at $2,032,881.Abbott Laboratories makes up approximately 1.51% of Mark Sheptoff Financial Planning’s portfolio.

Other Hedge Funds, Including , Ssi Investment Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 79 additional shares and now holds a total of 6,973 shares of Abbott Laboratories which is valued at $314,134. Abbott Laboratories makes up approx 0.09% of Ssi Investment Management Inc’s portfolio.Sg Americas Securities boosted its stake in ABT in the latest quarter, The investment management firm added 33,689 additional shares and now holds a total of 147,609 shares of Abbott Laboratories which is valued at $6,635,025. Abbott Laboratories makes up approx 0.05% of Sg Americas Securities’s portfolio.Prospera Financial Services Inc boosted its stake in ABT in the latest quarter, The investment management firm added 1,047 additional shares and now holds a total of 10,319 shares of Abbott Laboratories which is valued at $450,631. Abbott Laboratories makes up approx 0.09% of Prospera Financial Services Inc’s portfolio.Macguire Cheswick Tuttle Investment Counsel boosted its stake in ABT in the latest quarter, The investment management firm added 750 additional shares and now holds a total of 106,728 shares of Abbott Laboratories which is valued at $4,607,448. Abbott Laboratories makes up approx 0.99% of Macguire Cheswick Tuttle Investment Counsel’s portfolio.Cutler Group Lp boosted its stake in ABT in the latest quarter, The investment management firm added 3,700 additional shares and now holds a total of 18,200 shares of Abbott Laboratories which is valued at $763,854. Abbott Laboratories makes up approx 0.05% of Cutler Group Lp’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $44.68 with 86,30,316 shares getting traded on Wednesday. Post opening the session at $45.14, the shares hit an intraday low of $44.44 and an intraday high of $45.14 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *